We’re always excited to find bio/pharma companies nearing their therapeutic product launch! These 4 companies have FDA final approval decision (PDUFA) dates before the end of January: Atara Biotherapeutics (NASDAQ: ATRA ) Drug/Therapy: Tab-cel (tabelecleucel) Allogeneic T-cell immunotherapy Indication: Post-Transplant Lymphoproliferative Disease (PTLD) PDUFA date: January 15, 2025 BLA with priority review Biogen (NASDAQ: BIIB ) Drug/Therapy: Leqembi (Lecanemab) IV Maintenance

We’re always excited to find bio/pharma companies nearing their therapeutic product launch!

Big PDUFA from a big collaboration: BIIB & SAGE PDUFA - 8/5/23 - Zuranolone in MDD & PPD Collaboration since 2020… BIIB invested $1.5B in...

Summary: Biogen and Eisai's asset Lecanemab has a PDUFA date set for Friday 1/6/23 Lecanemab targets and effectively reduces beta-amyloid...

Biotech stocks are down ~40% since Jan 1, 2021, underperforming the broader markets The democratic white house and Congress since January...

At BPIQ we have started to track quarterly 13F filings for some of the largest biotech hedge funds. Q1 2022 13F filings were made on or...